Madison Square Garden (NYSE:MSGE) Stock, Quote.Headers.trade-ideas

Madison Square Garden

Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.

Wall Street US stocks

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

APEI

MSGE

Over $34M Bet On Comstock Resources? Check Out These 3 Stocks Executives Are Buying

MSGE WC

Earnings

Equities

Movers

Madison Square Garden stock rose after reporting fiscal Q4 results with 26% revenue growth to $186.1M, missing estimates. 

Madison Square Garden Q4: Topline Growth, Events And Merchandise Lead Charge

StockMarket analysts

Price Target

Analyst Ratings

Madison Square Garden Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Madison Square Garden Entertainment Corp. Class A Common Stock

Madison Square Garden Entertainment Corp

ICL Expands In China With New Food Specialty Plant In Zhangjiagang Free Trade Zone, Focuses On Innovative Solutions For Meat, Poultry, And Seafood Segments

Biotech

General

ENLV

Enlivex Receives DSMB Recommendation To Proceed With Phase II Stage Of Allocetra Trial For Moderate To Severe Knee Osteoarthritis After Successful Phase I Safety Review

Contracts

VRAR

The Glimpse Group Partners With The College Of Staten Island To Provide Technologies For Innovation Hub; Entered Into Two-Year Mix-Six Figure Contract

SRZN

Surrozen Earns $10M Milestone Payment As Boehringer Advances Development Of SZN-413 For Retinal Vascular Diseases, Prepares For Clinical Testing

Legal

VTAK

Catheter Precision Received Chinese Patent For LockeT

UGRO

urban-gro Wins Contract For Architectural Design Services For University Student Center Renovation At Columbia State University; Terms Not Disclosed

Piper Sandler analyst Michael Lavery maintains Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Overweight and lowers the price target from $50 to $47.

CELH

Piper Sandler Maintains Overweight on Celsius Holdings, Lowers Price Target to $47

CRH PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) company disclosed that its CEO Albert Manifold <a href="https://www.benzinga.com/pressreleases/24/09/b40995127/crh-announces-ceo-succession" target="_blank" rel="noreferrer noopener">will retire at the end of 2024</a>.
Manifold will be succeeded by Jim Mintern, CRH&#8217;s Chief Financial Officer and board director since June 2021.
Manifold, who joined CRH in 1998 and became CEO in January 2014, will step down from the board and his executive responsibilities on December 31, 2024.
Richie Boucher, Chairman of CRH, said, &#8220;The Board has a significant focus on succession planning throughout CRH. With the support of independent advisors, we have followed best practice, including a review of external candidates, and we have carefully monitored the development plans for potential internal candidates.&#8221;
&#8220;Over recent years we have closely observed Jim&#8217;s character, qualities and abilities, as well as his significant influence on the evolution of CRH. We are very pleased to have a successor of such caliber and are confident that Jim is best positioned to lead the CRH team, building the future of the company for the benefit of our investors, customers, colleagues and communities.&#8221;
Investors can gain exposure to the stock via Invesco Building &amp; Construction ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKB#NYSE">PKB</a>) and Fidelity MSCI Materials Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMAT#NYSE">FMAT</a>).
Price Action: CRH shares are down 0.94% at $91.11 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/40999268" target="_blank" rel="noreferrer noopener">Tesla Stock Poised For More Gains After Erasing Losses For The Year: What&#8217;s Charging Up The EV Maker?</a></li>
</ul>

Large Cap

Management

FMAT

PowerShares ETF Trust Dynamic Building &nstruction Portfolio

Big Changes At Building Products Company CRH: CEO Albert Manifold Set To Retire, CFO Jim Mintern Gears Up To Lead In 2025

BNZI

Banzai Announces $24.8M Debt Payoff And Restructuring Agreements With Insider Participation, Reducing Debt Burden And Extending Maturity To 2027

Granite Awarded $113M Contract To Support U.S. Marines Relocation

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://widgets.benzinga.com/analyst-stock-ratings/analyst/60f00f67c9514d0001c5b305/charlene-liu">HSBC analyst Charlene Liu</a> downgraded the rating for Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) from Buy to Hold and announced a price target of $100. Baidu shares gained 2.4% to close at $88.28 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other </a><a href="https://www.benzinga.com/quote/bidu/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">view this stock</a>.</li>
<li>Redburn Atlantic analyst Peter Low downgraded the rating for BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Buy to Neutral. BP shares gained 0.7% to close at $32.86 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this </a><a href="https://www.benzinga.com/quote/BP/analyst-ratings">stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell </a>downgraded McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Outperform to Neutral and lowered the price target from $603 to $531. McKesson shares fell 0.6% to close at $505.00 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See</a><a href="https://www.benzinga.com/quote/MCK/analyst-ratings"> </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Andrew Berens downgraded the rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Outperform to Market Perform, while cutting the price target from $1,175 to $1,077. Regeneron Pharmaceuticals shares fell 4.6% to close at $1,091.98 on Monday. <a href="https://www.benzinga.com/quote/REGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59c264af6e84a70001eb1bb8/david-chiaverini">Wedbush analyst David Chiaverini </a>downgraded First Horizon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) from Outperform to Neutral and slashed the price target from $20 to $17. First Horizon shares fell 1.9% to close at $15.67 on Monday. <a href="https://www.benzinga.com/quote/FHN/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
</ul>
Considering buying BP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/c9689ca0-032e-42a9-818e-8c799d42f940" alt="" style="width:618px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Downgrades

BIDU

REGN

This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Companies Targeting Closing in Fourth Quarter of 2024
Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/EVFM#OTCQB">EVFM</a>), today filed a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fapp.quotemedia.com%2Fdata%2FdownloadFiling%3FwebmasterId%3D101533%26ref%3D318604913%26type%3DHTML%26symbol%3DEVFM%26cdn%3Daa965ae7d29bd4fb48009ea93f2217c9%26companyName%3DEvofem%2BBiosciences%2BInc.%26formType%3DPRE%2B14A%26dateFiled%3D2024-09-23&amp;esheet=54126410&amp;newsitemid=20240924145198&amp;lan=en-US&amp;anchor=preliminary+proxy&amp;index=1&amp;md5=db30e6831fb84e7ccf45f998ac0d37d0">preliminary proxy</a> to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the "Merger Agreement"), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt ("Adifem"), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt.
Assuming the proposal is approved by Evofem stockholders and other closing conditions are met, including but not limited to the Company raising sufficient capital to fund its obligations at closing, the companies are targeting closing the transaction in the fourth quarter of 2024. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

ADTX

EVFM

Evofem Biosciences Files Preliminary Proxy For Stockholder Approval Of The Acquisition By Aditxt, Companies Targeting Closing In Q4 Of 2024

LPTH

LightPath Technologies Secures $3.5M Follow-On Order To Provide Advanced Infrared Optics For F-35 Combat Aircraft Program

Piper Sandler analyst Korinne Wolfmeyer initiates coverage on Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Neutral rating and announces Price Target of $174.

Initiation

Piper Sandler Initiates Coverage On Procter & Gamble with Neutral Rating, Announces Price Target of $174

Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) with a Overweight and maintains $13 price target.

Reiteration

MRNS

Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $13 Price Target

<ul>
<li>An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.</li>
<li>The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification.
<ul>
<li>Final Clinical Safety Data for Simufilam Are Expected at the Conclusion of the Phase 3 Program. &nbsp;</li>
</ul>
</li>
</ul>

SAVA

Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials

Aurinia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUPH#NASDAQ">AUPH</a>) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN).
The Company's collaboration partner, Otsuka Pharmaceutical Co., Ltd., filed the new drug application (NDA) with Japanese regulatory authorities in November 2023. The approval is based on data from the AURORA Clinical Program, which included a 12-month, Phase 3, double-blind, randomized-controlled study, as well as a two-year extension study, assessing the efficacy and safety of voclosporin with MMF and low-dose glucocorticoids, compared to MMF and low-dose glucocorticoids alone, in LN patients.

Global

AUPH

Aurinia Announces Japan Approval Of LUPKYNIS To Treat Lupus Nephritis

ANIX

Anixa Biosciences Announces Phase 2 Study Plan for Breast Cancer Vaccine; Phase 2 Trial Will Evaluate Efficacy Of Vaccine Administered In The Neoadjuvant Setting In Combination With Keytruda And Chemotherapy

WIIM

CRMT

America's Car-Mart shares are trading higher after the company appointed Jamie Fischer as COO.

Piper Sandler analyst Korinne Wolfmeyer initiates coverage on Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight rating and announces Price Target of $121.

Piper Sandler Initiates Coverage On Colgate-Palmolive with Overweight Rating, Announces Price Target of $121

Today, several major companies are expected to report earnings: Flowers Foods (FLO), Kandi Technologies (KNDI), OneConnect Financial Technology (OC...

Options Volatility and Implied Earnings Moves Today, August 16, 2024

Madison Square Garden's food and beverage sales help fuel 26% revenue growth

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Madison Square Garden (NYSE:<a href="https://investorplace.com/stock-quotes/msge-stock-quote/">MSGE</a>) just reported results for the fourth quarter of 2024.<ul><li>Madison Square Garden reported earnings per share of -53 cents. This was below the analyst estimate for EPS of -52 cents.</li><li>The company reported revenue of $186.07 million.</li><li>This was 9.71% better than the analyst estimate for revenue of $169.61 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/msge-stock-earnings-madison-square-garden-for-q4-of-2024/">MSGE Stock Earnings: Madison Square Garden Misses EPS, Beats Revenue for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MSGE Stock Earnings: Madison Square Garden Misses EPS, Beats Revenue for Q4 2024

Madison Square Garden Entertainment GAAP EPS of $1.41 beats by $1.97, revenue of $186.07M beats by $16.86M

Madison Square Garden Entertainment Corp. (MSGE) Q4 2024 Earnings Call Transcript

Companies in the Consumer Cyclical sector have received a lot of coverage today as analysts weigh in on Madison Square Garden Entertainment Corp. (...

Analysts Offer Insights on Consumer Cyclical Companies: Madison Square Garden Entertainment Corp. (MSGE), Peloton Interactive (PTON) and Yeti Holdings (YETI)

There's a lot to be optimistic about in the Consumer Cyclical sector as 2 analysts just weighed in on Taylor Morrison (TMHC – Research Report) and ...

Analysts Offer Insights on Consumer Cyclical Companies: Taylor Morrison (TMHC) and Madison Square Garden Entertainment Corp. (MSGE)

There's a lot to be optimistic about in the Consumer Cyclical sector as 3 analysts just weighed in on Madison Square Garden Entertainment Corp. (MS...

Analysts Offer Insights on Consumer Cyclical Companies: Madison Square Garden Entertainment Corp. (MSGE), Portillo's (PTLO) and Tapestry (TPR)

Madison Square Garden Entertainment: Demand Remains Robust

Tracking John Rogers' Ariel Investments Portfolio - Q2 2024 Update

APTV

ATGE

BAIDF

BOKF

CHKP

GILD

GNRC

GNTX

KNDI

MGRB

MGRD

MGRE

MSFT

NTRS

NTRSO

OCFT

PARA

PARAA

PTLO

PTON

REZI

SAEF

SPHR

TMHC

YETI

ZBRA

Entertainment

Press Releases

Madison Square Garden Entertainment Corp. to Host Fiscal 2024 Second Quarter Conference Call

MSG ENTERTAINMENT NAMES MICHAEL GRAU EXECUTIVE VICE PRESIDENT, FINANCE

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2024 SECOND QUARTER RESULTS

GARDEN OF LAUGHS RETURNS WITH ALL-STAR COMEDY LINEUP FEATURING BILL BURR, MICHAEL CHE, CHRIS DISTEFANO, JIM GAFFIGAN, HEATHER MCMAHAN, SAM MORRIL AND JON STEWART

Commodities

EARTH BRANDS NAMED AN OFFICIAL PARTNER OF MADISON SQUARE GARDEN

Madison Square Garden Entertainment Corp. to Host Fiscal 2024 Third Quarter Conference Call

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2024 THIRD QUARTER RESULTS

Madison Square Garden Entertainment Corp. to Host Fiscal 2024 Fourth Quarter and Year-End Conference Call

MADISON SQUARE GARDEN ENTERTAINMENT CORP. REPORTS FISCAL 2024 FOURTH QUARTER AND FULL YEAR RESULTS

Small Cap

THE MSG FAMILY OF COMPANIES LAUNCH EXPANSIVE MULTI-YEAR PARTNERSHIP WITH GLOBAL TECHNOLOGY POWERHOUSE LENOVO AND SUBSIDIARY MOTOROLA

LNVGY

MSGS

AMC Entertainment Holdings, Inc. Class A Common Stock

AMC Enter Hldgs

Atlanta Braves Holdings, Inc. - Series A Common Stock

Atlanta Braves Holdings

Atlanta Braves Holdings, Inc. - Series C Common Stock

Cinemark Holdings Inc Cinemark Holdings, Inc. Common Stock

Cinemark Hldgs

Walt Disney

Endeavor Group Holdings, Inc. Class A Common Stock

Endeavor Gr Hldgs

Liberty Media Corporation - Series A Liberty Formula One Common Stock

Liberty Formula One Gr

Ordinary Shares (New Liberty Formula One) Series A

Liberty Media Corporation - Series C Liberty Formula One Common Stock

Ordinary Shares (New Liberty Formula One) Series C

iQIYI

Lions Gate Entertainment Corporation Class A Voting Shares

Lions Gate Entertainment Corporation Class B Non-Voting Shares

Lionsgate Studios

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live

Ordinary Shares (New Liberty Live) Series A

Liberty Media Corporation - Series C Liberty Live Common Stock

Ordinary Shares (New Liberty Live) Series C

Live Nation Entertainment, Inc. Common Stock

Live Nation Entertainment

Manchester United Ltd. Class A Ordinary Shares

Manchester United

Madison Square Garden Sports Corp. Class A Common Stock (New)

Netflix

Roku

Reservoir Media

Sphere Entertainment Co. Class A Common Stock

Sphere Entertainment

TKO Group Holdings, Inc. Class A Common Stock

TKO Group Holdings

Tencent Music Entertainment Group American Depositary Shares, each representing two Class A Ordinary Shares

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Madison Square Garden

Madison Square Garden (MSGE) Forecast

Madison Square Garden (NYSE:MSGE) Stock, Quote.Headers.trade-ideas